Legend Biotech Corporation
LEGN · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.27 | 0.02 | -0.23 | -0.02 |
| FCF Yield | -0.68% | -3.39% | -2.84% | -1.75% |
| EV / EBITDA | -29.69 | -34.19 | 57.93 | -39.48 |
| Quality | ||||
| ROIC | -1.54% | -3.70% | -3.44% | -4.93% |
| Gross Margin | 59.29% | 63.42% | 60.37% | 65.38% |
| Cash Conversion Ratio | -0.74 | 0.10 | 1.05 | -2.03 |
| Growth | ||||
| Revenue 3-Year CAGR | 57.35% | 69.15% | 91.75% | 79.59% |
| Free Cash Flow Growth | 78.95% | -25.22% | -8.43% | -1,436.84% |
| Safety | ||||
| Net Debt / EBITDA | -1.06 | 0.89 | 1.22 | 1.03 |
| Interest Coverage | -4.19 | -10.01 | -14.44 | -12.73 |
| Efficiency | ||||
| Inventory Turnover | 2.93 | 2.31 | 3.09 | 2.36 |
| Cash Conversion Cycle | 46.17 | 42.66 | 44.08 | 52.96 |